Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up.

ABSTRACT:

Background

The identification of new biomarkers of heart failure (HF) could help in its treatment. Previously, our group studied 89 patients with HF and showed that exhaled breath acetone (EBA) is a new noninvasive biomarker of HF diagnosis. However, there is no data about the relevance of EBA as a biomarker of prognosis.

Objectives

To evaluate whether EBA could give prognostic information in patients with heart failure with reduced ejection fraction (HFrEF).

Methods

After breath collection and analysis by gas chromatography-mass spectrometry and by spectrophotometry, the 89 patients referred before were followed by one year. Study physicians, blind to the results of cardiac biomarker testing, ascertained vital status of each study participant at 12 months.

Results

SUBMITTER: Marcondes-Braga FG 

PROVIDER: S-EPMC5193433 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature